Shortly after claiming FDA approval for its Filspari therapy for rare kidney disease IgA Nephropathy (IgAN), Travere Therapeutics has said it will price the drug at a discount to a recently-approved ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...

Moderna saw its first-quarter revenues nearly triple to $389 million compared to the same period of 2025, with international ...

For years, conversations about artificial intelligence (AI) in life sciences have alternated between hype and hesitation.

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

From chip giant NVIDIA agreeing a $2 billion partnership with AI cloud provider Nebius, to Roche ramping up its investment in ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

The first data has emerged on the uptake of Novo Nordisk's new oral version of GLP-1 agonist weight-loss therapy Wegovy, with encouraging signs of strong demand as a potential rival from Eli Lilly ...

US MFN rules and new tariffs are narrowing the US–ex-US price gap and drawing more manufacturing and capital investment toward the United States. Low European or UK list prices now directly affect US ...

After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate ...

In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...